{"title":"双特异性抗体治疗复发性淋巴瘤","authors":"Michael E. Williams","doi":"10.1056/NEJM-JW.NA54216","DOIUrl":null,"url":null,"abstract":"Bispecific therapeutic monoclonal antibodies are an emerging treatment option for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and multiple","PeriodicalId":19048,"journal":{"name":"NEJM Journal Watch","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bispecific Antibody Therapy for Relapsed Lymphoma\",\"authors\":\"Michael E. Williams\",\"doi\":\"10.1056/NEJM-JW.NA54216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bispecific therapeutic monoclonal antibodies are an emerging treatment option for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and multiple\",\"PeriodicalId\":19048,\"journal\":{\"name\":\"NEJM Journal Watch\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NEJM Journal Watch\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1056/NEJM-JW.NA54216\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEJM Journal Watch","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/NEJM-JW.NA54216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}